CD8A and myeloid sarcoma: Alemtuzumab, an anti-CD52 monoclonal antibody used as a treatment for MS, frequently induces AIT (in 20% to 33% of patients), probably due to rapid recovery of CD8 T-lymphocytes after alemtuzumab-induced lymphocytes depletion [18].